Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367.
Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome. For more information please click here.